APOA1 and atherosclerosis: Anti-HDL antibody, anti-ApoA1 antibody, and anti-paraoxonase 1 (PON1) antibody are likely to share a common atherogenic pathway in that they disrupt the balance of PON1/MPO, which increases oxidative lipid modification and interferes with HDL's anti-inflammatory activity, all of which contribute to atherosclerosis [35-37].